Anzeige
Mehr »
Montag, 07.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0ESMG | ISIN: FR0010259150 | Ticker-Symbol: I7G
Tradegate
07.07.25 | 08:00
103,90 Euro
+0,68 % +0,70
1-Jahres-Chart
IPSEN SA Chart 1 Jahr
5-Tage-Chart
IPSEN SA 5-Tage-Chart
RealtimeGeldBriefZeit
102,60102,9009:35
102,60102,8009:34

Aktuelle News zur IPSEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiIpsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 20253
DiEQS-News: Ipsen Pharma GmbH: Gemeinsam für eine bessere Zukunft: Ipsen Pharma GmbH engagiert sich am Community Day 2025 für Menschen und Umwelt299EQS-News: Ipsen Pharma GmbH / Schlagwort(e): Sonstiges Gemeinsam für eine bessere Zukunft: Ipsen Pharma GmbH engagiert sich am Community Day 2025 für Menschen und Umwelt 01.07.2025...
► Artikel lesen
26.06.Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours2
24.06.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 20251
20.06.Madrigal, Ipsen, SpringWorks get EU backing for their drugs2
20.06.CHMP Issues Positive Opinion On Ipsen's Cabometyx For Advanced PNET And EpNET Patients1
20.06.Exelixis, Inc.: Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors358- A regulatory decision by the European Medicines Agency is anticipated in 2025 - - In March 2025, the U.S. Food and Drug Administration approved CABOMETYX in this setting - Exelixis, Inc....
► Artikel lesen
20.06.Ipsen Pharma: Ipsen receives positive CHMP opinion for Cabometyx in previously treated advanced neuroendocrine tumors457If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin...
► Artikel lesen
IPSEN Aktie jetzt für 0€ handeln
17.06.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 20251
13.06.Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 20251
12.06.Ipsen Pharma: Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital1
06.06.Dividendenbekanntmachungen (06.06.2025)13.401 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  AAON INC  US0003602069  0,1 USD  0,0873 EUR  ALBANY INTERNATIONAL CORP  US0123481089  0,27 USD  0,2358 EUR  ARCA CONTINENTAL SAB DE CV  MX01AC100006  3...
► Artikel lesen
04.06.Dividendenbekanntmachungen (04.06.2025)9.876 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ADESSO SE  DE000A0Z23Q5 - 0,75 EUR  AGEAS SA/NV  BE0974264930 - 2 EUR  AIR LEASE CORPORATION  US00912X3026  0,22 USD  0,1934 EUR  ANALOG...
► Artikel lesen
04.06.Deutsche Bank resumes Ipsen stock with buy rating citing Somatuline5
02.06.Ipsen Pharma: Ipsen S.A. - Initiation of the share buy-back program1
31.05.Ipsen Pharma: Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma625Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics...
► Artikel lesen
21.05.Ipsen Pharma: Ipsen S.A. - Annual General Meeting held on 21 May 2025429Annual General Meeting of Ipsen S.A. held on 21 May 2025 All the resolutions submitted to the shareholders' vote have been adopted PARIS, FRANCE, 21 May 2025 - Ipsen (Euronext: IPN; ADR: IPSEY)...
► Artikel lesen
20.05.GENFIT S.A.: GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo in Italy266Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients...
► Artikel lesen
12.05.Ipsen Pharma: Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital4
07.05.Ipsen Pharma: Late-breaking exploratory data highlights the impact of IQIRVO (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis589Additional late-breaking data suggests up to twice as many patients treated with IQIRVO® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 weeks of treatmentIQIRVO...
► Artikel lesen
Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1